Dutch interest group calls for excessive drug-pricing probe
An advocacy group has said it will ask the Netherlands’ competition authority to investigate a drugmaker for setting excessive prices for the only drug that is available on the market for treating a rare genetic disease.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now